key: cord-0926949-verzxars
authors: Apaydın, Çağla Begüm; Cesur, Nesrin; Stevaert, Annelies; Naesens, Lieve; Cesur, Zafer
title: Synthesis and anti‐coronavirus activity of a series of 1‐thia‐4‐azaspiro[4.5]decan‐3‐one derivatives
date: 2019-05-09
journal: Arch Pharm (Weinheim)
DOI: 10.1002/ardp.201800330
sha: 9b2209190acc4d0c8adf1893681612471fb0aa5b
doc_id: 926949
cord_uid: verzxars

A series of 1‐thia‐4‐azaspiro[4.5]decan‐3‐ones bearing an amide group at C‐4 and various substitutions at C‐2 and C‐8 were synthesized and evaluated against human coronavirus and influenza virus. Compounds 7m, 7n, 8k, 8l, 8m, 8n, and 8p were found to inhibit human coronavirus 229E replication. The most active compound was N‐(2‐methyl‐8‐tert‐butyl‐3‐oxo‐1‐thia‐4‐azaspiro[4.5]decan‐4‐yl)‐3‐phenylpropanamide (8n), with an EC(50) value of 5.5 µM, comparable to the known coronavirus inhibitor, (Z)‐N‐[3‐[4‐(4‐bromophenyl)‐4‐hydroxypiperidin‐1‐yl]‐3‐oxo‐1‐phenylprop‐1‐en‐2‐yl]benzamide (K22). Compound 8n and structural analogs were devoid of anti‐influenza virus activity, although their scaffold is shared with a previously discovered class of H3 hemagglutinin‐specific influenza virus fusion inhibitors. These findings point to the 1‐thia‐4‐azaspiro[4.5]decan‐3‐one scaffold as a versatile chemical structure with high relevance for antiviral drug development.

Hydrazides (3, 4) were obtained by stepwise reactions, firstly by esterification of acids in methanol in the presence of H 2 SO 4 to give esters (1, 2) , and secondly hydrazinolysis of 1, 2 to give 3, 4. [10] 3, 4 were reacted with cyclic ketones to afford corresponding derivatives 5, 6 that are commercially available or recorded earlier, except 5a and 6a. [11, 12] Spectral and analytical data of 5a and 6a are given under "General procedure for the synthesis of N'-(cycloalkylidene)-2-phenoxyacetohydrazides (5) or N'-(cycloalkylidene)-3-phenylpropanehydrazides (6)".

Cyclocondensation of 5 or 6 with sulphanylacetic acid or 2-sulphanylpropanoic acid led to N-(substituted 3-oxo-1-thia-4-azaspiro [4.4] non-4-yl/ [4.5] dec-4-yl/ [4.6] undec-4-yl)-2-phenoxyacetamide (7) or N-(substituted 3-oxo-1-thia-4-azaspiro [4.4] non-4-yl/ [4.5] decan-4-yl)-3-phenylpropanamides (8) . The first evidence for the formation of 7 and 8 was the observation of a new band between 1728-1697 cm −1 in their IR spectra due to 3-carbonyl group. The C=O stretching band of the carboxamide moiety was also observed at 1660-1693 cm −1 . Bands between 3468-3167 cm −1 region confirmed the presence of NH stretching bands. In the 1 H-NMR spectra of 7, CONH protons were observed at δ 9.91-10.59 ppm as singlets. C 2 -methylene protons of 7a-g and 8a-h resonated at δ 3.52-3.64 ppm as singlets, while C 2 -methine protons of 7h-n and 8i-p gave quartets at δ 3.80-3.93 ppm. The 13 C-NMR spectra of 7a-m and 8j

showed spirothiazolidinone C 2 carbon (δ 27.76-38.08 ppm) and spirothiazolidinone C=O carbon (δ 167.59-170.77 

The compounds were evaluated for antiviral activity against human coronavirus 229E in HEL 299 fibroblast cells, and against influenza A/H1N1, A/H3N2, and B viruses in MDCK cells. The test compounds can be classified in either Group 7, carrying a phenoxyethyl side chain, or Group 8, with a phenethyl side chain. Our previously discovered H3 hemagglutinin-specific influenza virus fusion inhibitors [9] have the same scaffold but carry an imidazo [2,1-b] position of the azaspiro [4.5] decane (R 1 ), whereas the unmethylated analogs (i.e., 7e, 7f, 8c, 8d, 8e, 8f, 8h) were devoid of antiviral activity. The same observation was previously made for the structurally related influenza virus fusion inhibitors. [9] In addition, for compound series 8, the anti-coronavirus activity clearly depended on the bulkiness of the C-8 substituent of the azaspiro [4.5] 

We report the chemical synthesis of a compound series with 4carboxamido-3-oxo-1-thia-4-azaspiro [4.4] nonan/ [4.5] (2) A solution of phenoxyacetic acid (0.01 mol) or 3-phenylpropionic acid (0.01 mol) and sulfuric acid (98%) (0.1 ml) in 50 ml of methanol was heated for 24 hr. The solution was neutralized with 0.01 mol of sodium bicarbonate solution, the mixture was extracted with diethyl ether and, after distillation of solvent, the ester was used without further purification. [10, 13] 

A mixture of 1 or 2 (0.01 mol), ethanol (50 ml), and hydrazine (0.0125 mol) was refluxed for 1 hr. The solid was filtered off, washed with cold water and used without recrystallization. [10, 13] 4.1.4 | General procedure for the synthesis of N'-(cycloalkylidene)-2-phenoxyacetohydrazides (5) or N'-(cycloalkylidene)-3-phenylpropanehydrazides (6) A solution of hydrazide (3 or 4) and appropriate ketone (0.01 mol) in 20 ml of ethanol (96%) was refluxed for 1-3 hr and then the solution was allowed to cool. The solid thus formed was filtered off, dried and directly used in the next step. H: 5.45, N: 8.91. Found: C: 57.19, H: 5.40, N: 8.94. N'- 4.1.5 | General procedure for the synthesis of N-(substituted 3-oxo-1-thia-4-azaspiro [4.4] non-4-yl/ [4.5] dec-4-yl/ [4.6] undec-4-yl)-2-phenoxyacetamides (7) and N-(substituted 3-oxo-1-thia-4-azaspiro [4.4] non-4-yl/ [4.5] decan-4-yl)-3-phenylpropanamides (8) A mixture of 5 or 6 (0.005 mol) and sulfanylacetic acid or 2sulfanylpropanoic acid (1.5 ml) in 30 ml of dried toluene was refluxed for 4-10 hr, using a Dean Stark water separator. Toluene was evaporated in vacuo. The residue was neutralized with saturated sodium bicarbonate and was allowed to solidify. The crude product was filtered and recrystallized from ethanol or ethanol/water mixture. CH 3 ), 1.24-1.45 (2H, m, spirodecane C 7,9-ax -H), 1.50 (1H, broad d, J = 13 Hz, spirodecane C 8-eq -H), 1.56-1.78 (6H, m, C 6,10 -H, C 7,9-eq -H), 3.87 (1H, q, J = 7 Hz, spirodecane C 2 -H), 4.69 (2H, s, OCH 2 ), 6.96-7.02 (3H, m, phenyl C 2,4,6 -H), 7.29-7.34 (2H, m, phenyl C 3,5 H: 6.63, N: 8.38. Found: C: 61.24, H: 6.46, N: 8.50. N- (2, 13, 31.62, 37.53 (spirodecane C 6,7,9,10 ) , 36.65 (spirodecane C 2 ), 65.96 (OCH 2 ), 70.65 (spirodecane C 5 ), 114.69, 114.78, 121.20, 121.29, 129.42 (phenyl C 2-6 (6H, m, spirodecane C 7,9-eq -H, C 6,10 -H), 3.85 (H, q, J = 7 Hz, spirodecane C 2 -H), 4.68 (2H, s, OCH 2 ), 6.94-7.00 (3H, m, phenyl C 2,4,6 -H), 7.27-7.31 (2H, m, phenyl C 3,5 -H), 10.34 (1H, s, NH). 13 C-NMR (proton decoupled) (DMSO-d 6 /100 MHz): 19.50 (spirodecane C 2 -CH 3 ), 23.38, 23.82, 36.90, and 37.60 (spirodecane C 6,7,9,10 ) , 27.16 (tert-butyl CH 3 ), 31.77 (tert-butyl C), 36.60 (spirodecane C 2 ), 45.50 (spirodecane C 8 ), 65.90 (OCH 2 ), 70.73 (spirodecane C 5 ), 114.61, 114.76, 121.24, 129.33 (phenyl C 2-6 1.48-1.71 (2H, m, spirodecane C 7,9-ax -H), 1.73-2.03 (6H, m, spirodecane C 7,9-eq -H, C 6,10 -H), 2.35 (1H, broad t, J = 13 Hz, spirodecane C 8 -H), 3.93 (1H, q, J = 8 Hz, spirodecane C 2 -H), 4.73 (2H, s, OCH 2 ), m, phenoxy C 2, 4, m, phenoxy C 3, m, 10.44 (1H, s, NH) . 13 C-NMR (proton decoupled) (DMSO-d 6 /100 MHz): 18.46 (spirodecane C 2 -CH 3 ), 30. 12, 30.68, 36.85, 37.71 (spirodecane C 6,7,9,10 H: 7.06, N: 6.14. Found: C: 65.48, H: 6.79, N: 6.50. N- m, spirononane C [6] [7] [8] [9] CH 2 , 2.86 (2H, t, J = 7 Hz, CH 2 ), 3.61 (2H, s, m, 9.97 (1H, s, NH) . Anal. calcd. for C 16 H 20 N 2 O 2 S (304.40): C: 63.13, H: 6.62, N: 9.20. Found: C: 63.08, H: 6.71, m, 9.91 (1H, s, NH H: 7.28, N: 8.43. Found: C: 64.77, H: 7.11, N: 8.49. N- (2, 

96 (1H, s, NH). Anal. calcd. for C 19 H 26 N 2 O 2 S

Ethyl-2-methyl-3-oxo-1-thia-4-azaspiro

Yield: 94%. mp

IR (KBr) ʋ (cm −1 ): 3310, 3186 (N-H), 1720 (C=O), 1674 (NHC=O). 1 H-NMR (DMSO-d 6 /500 MHz): 0.81

CH 3 ), 1.16 (2H, qu, J = 7 Hz, spirodecane C 8 -CH 2 )

97 (1H, s, NH). Anal. calcd

Methyl-3-oxo-8-propyl-1-thia-4-azaspiro

Yield: 93%. mp

IR (KBr) ʋ (cm −1 )

27 (2H, m, spirodecane C 8 -CH 2 ), 1.37 (3H, d, J = 7 Hz, C 2 -CH 3 ), 2.49-2.52 (m, CH 2 , and DMSO-d 6 ), 2.86 (2H, t

Yield: 100%. mp

IR (KBr) ʋ (cm −1 )

62 (9H, m, spirodecane C 6-10 ), 0.82 (9H, s, CH 3 ), 1.37 (3H, d

CH 2 ), 3.82 (1H, q, J = 7 Hz, spirodecane C 2 -H)

Yield: 95%. mp

1660 (NHC=O). 1 H-NMR (DMSO-d 6 /500 MHz): 1.27-2.09 (9H, m, spirodecane C 6-10 ), 1.39 (3H, d

Anal. calcd. for C 19 H 23 F 3 N 2 O 2 S (418

Yield: 96%. mp

1668 (NHC=O). 1 H-NMR (DMSO-d 6 /500 MHz): 1.04-2.31 (9H, m, spirodecane C 6-10 ), 1.41 (3H, d, J = 7 Hz, C 2 -CH 3 ), 2.49-2.56 (m, CH 2 , and DMSO-d 6

The HCoV-229E stock was obtained from ATCC (VR-740™) and expanded in human embryonic lung (HEL) 299 fibroblast cells (ATCC CCL-137™). For the CPE reduction assay, HEL cells were seeded in 96-well plates and grown for 6 days until they reached confluence. The influenza virus strain A/HK/7/87 (A/H3N2) was a kind gift from J. Neyts (Leuven, Belgium), whereas the clinical isolates A/Ned/ 378/05 (A/H1N1) and B/Ned/537/05 were generously provided by

minimum cytotoxic concentration producing minimal changes in cell morphology. For HCoV-229E, K22 [(Z)-N-[3-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-3-oxo-1-phenylprop-1-en-2-influenza virus: ribavirin (Virazole from ICN Pharmaceuticals, Costa, CA), rimantadine and amantadine (both from Sigma-Aldrich, Belgium)

Fields' virology

Learning from SARS: Preparing for the next disease outbreak: workshop summary

Middle East respiratory syndrome: situation update

Synthesis and anti-coronavirus activity of a series of 1-thia-4-azaspiro